惊了！39岁董秘被留置！

Core Viewpoint - The announcement regarding the detention of Li Zhe, the director, board secretary, and vice president of Ruikang Pharmaceutical, raises concerns about the company's governance and operational stability, although the company asserts that it will not significantly impact its normal operations [2][5][6]. Company Governance - Li Zhe has been placed under detention by the Jinan Municipal Jiyang District Supervisory Committee, which prevents him from fulfilling his duties as board secretary [2][5]. - Wang Xiuting, the company's securities affairs representative, will temporarily assume the responsibilities of the board secretary during Li Zhe's detention [5]. - Ruikang Pharmaceutical claims to have a robust governance structure and internal control mechanisms, with other board members and senior management continuing to perform their duties normally [6]. Financial Performance - Ruikang Pharmaceutical has experienced a decline in operating revenue for five consecutive years, indicating instability in its financial performance [9]. - The company's total revenue for the latest reporting period was 79.66 million, down 12.98% year-on-year [10]. - The net profit for the same period was 0.41 million, reflecting a year-on-year increase of 28.30% [10]. Executive Compensation - Li Zhe's annual salary for 2024 is reported to be 403,500 [7]. - The company has a diverse executive team with varying compensation levels, with the chairman earning 580,400 and other executives earning between 295,400 and 904,400 [8]. Market Position - As of July 2, the stock price of Ruikang Pharmaceutical was 3.01 per share, with a total market capitalization of 4.5 billion [11].